Pharsight

Corlanor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7879842 AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(2 years from now)

US7361650 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(2 years from now)

US7361649 AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(2 years from now)

US7867996 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Dec, 2026

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7361649

(Pediatric)

AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Aug, 2026

(2 years from now)

US7879842

(Pediatric)

AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Aug, 2026

(2 years from now)

US7361650

(Pediatric)

AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Aug, 2026

(2 years from now)

US7867996

(Pediatric)

AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Jun, 2027

(3 years from now)

Corlanor is owned by Amgen Inc.

Corlanor contains Ivabradine Hydrochloride.

Corlanor has a total of 8 drug patents out of which 0 drug patents have expired.

Corlanor was authorised for market use on 15 April, 2015.

Corlanor is available in tablet;oral dosage forms.

Corlanor can be used as a method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride.

The generics of Corlanor are possible to be released after 12 June, 2027.

Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 April, 2015

Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride

Dosage: TABLET;ORAL

How can I launch a generic of CORLANOR before it's drug patent expiration?
More Information on Dosage

CORLANOR family patents

Family Patents
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7361650 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(2 years from now)

US7361649 AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(2 years from now)

US7879842 AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(2 years from now)

US7867996 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Dec, 2026

(3 years from now)

Corlanor is owned by Amgen Inc.

Corlanor contains Ivabradine.

Corlanor has a total of 4 drug patents out of which 0 drug patents have expired.

Corlanor was authorised for market use on 22 April, 2019.

Corlanor is available in solution;oral dosage forms.

Corlanor can be used as a method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride.

The generics of Corlanor are possible to be released after 12 December, 2026.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 22, 2026
Pediatric Exclusivity (PED) Oct 22, 2026

Drugs and Companies using IVABRADINE ingredient

Market Authorisation Date: 22 April, 2019

Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride

Dosage: SOLUTION;ORAL

More Information on Dosage

CORLANOR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic